251 related articles for article (PubMed ID: 21240857)
1. Regression of serous macular detachment due to peripheral exudative hemorrhagic chorioretinopathy following intravitreal bevacizumab.
Barkmeier AJ; Kadikoy H; Holz ER; Carvounis PE
Eur J Ophthalmol; 2011; 21(4):506-8. PubMed ID: 21240857
[TBL] [Abstract][Full Text] [Related]
2. Treatment of macular serous neuroretinal detachment in tilted disk syndrome: report of 3 cases.
Donati MC; Miele A; Abbruzzese G; Giuntoli M; Giansanti F; Menchini U
Eur J Ophthalmol; 2013; 23(2):267-70. PubMed ID: 23225087
[TBL] [Abstract][Full Text] [Related]
3. Intravitreal triamcinolone versus intravitreal bevacizumab in the treatment of exudative retinal detachment secondary to posterior uveal melanoma.
Parrozzani R; Pilotto E; Dario A; Miglionico G; Midena E
Am J Ophthalmol; 2013 Jan; 155(1):127-133.e2. PubMed ID: 22995029
[TBL] [Abstract][Full Text] [Related]
4. RESPONSE TO INTRAVITREAL AFLIBERCEPT IN A PATIENT WITH PERIPHERAL EXUDATIVE HEMORRHAGIC CHORIORETINOPATHY.
Sax J; Karpa M; Reddie I
Retin Cases Brief Rep; 2021 May; 15(3):286-288. PubMed ID: 30074571
[TBL] [Abstract][Full Text] [Related]
5. Exacerbation of central serous chorioretinopathy following PASCAL photocoagulation.
Yang HS; Park SH
Can J Ophthalmol; 2013 Jun; 48(3):e42-3. PubMed ID: 23769790
[No Abstract] [Full Text] [Related]
6. Clinical characteristics of peripheral exudative hemorrhagic chorioretinopathy and its response to bevacizumab therapy.
Pinarci EY; Kilic I; Bayar SA; Sizmaz S; Akkoyun I; Yilmaz G
Eye (Lond); 2013 Jan; 27(1):111-2. PubMed ID: 23154499
[No Abstract] [Full Text] [Related]
7. Intravitreal bevacizumab to treat acute central serous chorioretinopathy: short-term effect.
Seong HK; Bae JH; Kim ES; Han JR; Nam WH; Kim HK
Ophthalmologica; 2009; 223(5):343-7. PubMed ID: 19521133
[TBL] [Abstract][Full Text] [Related]
8. [Efficacy of three intravitreal injections of bevacizumab in the treatment of exudative age-related macular degeneration].
Bidot ML; Malvitte L; Bidot S; Bron A; Creuzot-Garcher C
J Fr Ophtalmol; 2011 Jun; 34(6):376-81. PubMed ID: 21550687
[TBL] [Abstract][Full Text] [Related]
9. Anti-VEGF therapy in symptomatic peripheral exudative hemorrhagic chorioretinopathy (PEHCR) involving the macula.
Seibel I; Hager A; Duncker T; Riechardt AI; Nürnberg D; Klein JP; Rehak M; Joussen AM
Graefes Arch Clin Exp Ophthalmol; 2016 Apr; 254(4):653-9. PubMed ID: 26148802
[TBL] [Abstract][Full Text] [Related]
10. Intravitreal bevacizumab injection for peripheral exudative hemorrhagic chorioretinopathy.
Alforja MS; Sabater N; Giralt J; Adán A; Pelegrín L; Casaroli-Marano R
Jpn J Ophthalmol; 2011 Jul; 55(4):425-427. PubMed ID: 21633808
[No Abstract] [Full Text] [Related]
11. Treatment of serous macular detachment associated with circumscribed choroidal hemangioma.
Kwon HJ; Kim M; Lee CS; Lee SC
Am J Ophthalmol; 2012 Jul; 154(1):137-145.e1. PubMed ID: 22465363
[TBL] [Abstract][Full Text] [Related]
12. Intravitreal Bevacizumab for Traumatic Choroidal Rupture.
Kim M; Kim JH; Seo Y; Koh HJ; Lee SC
Optom Vis Sci; 2015 Oct; 92(10):e363-7. PubMed ID: 26367340
[TBL] [Abstract][Full Text] [Related]
13. Intravitreal bevacizumab for exudative age-related macular degeneration: effect on different subfoveal membranes.
Tao Y; Jonas JB
Retina; 2010 Oct; 30(9):1426-31. PubMed ID: 20539255
[TBL] [Abstract][Full Text] [Related]
14. Intravitreal bevacizumab for macular complications from retinal arterial macroaneurysms.
Pichi F; Morara M; Torrazza C; Manzi G; Alkabes M; Balducci N; Vitale L; Lembo A; Ciardella AP; Nucci P
Am J Ophthalmol; 2013 Feb; 155(2):287-294.e1. PubMed ID: 23111179
[TBL] [Abstract][Full Text] [Related]
15. Intravitreal bevacizumab injection for central serous chorioretinopathy.
Lim SJ; Roh MI; Kwon OW
Retina; 2010 Jan; 30(1):100-6. PubMed ID: 20010322
[TBL] [Abstract][Full Text] [Related]
16. The efficacy of intravitreal bevacizumab for idiopathic central serous chorioretinopathy.
Lim JW; Kim MU
Graefes Arch Clin Exp Ophthalmol; 2011 Jul; 249(7):969-74. PubMed ID: 21140161
[TBL] [Abstract][Full Text] [Related]
17. Results of one-year follow-up examinations after intravitreal bevacizumab administration for chronic central serous chorioretinopathy.
Inoue M; Kadonosono K; Watanabe Y; Kobayashi S; Yamane S; Arakawa A
Ophthalmologica; 2011; 225(1):37-40. PubMed ID: 20693820
[TBL] [Abstract][Full Text] [Related]
18. Intravitreal bevacizumab injection for central serous chorioretinopathy.
Nowroozzadeh MH
Retina; 2010 Sep; 30(8):1322-3; author reply 1323. PubMed ID: 20827148
[No Abstract] [Full Text] [Related]
19. Intravitreal bevacizumab injection for central serous chorioretinopathy.
Chhablani JK; Narayanan R
Retina; 2010 Sep; 30(8):1323-24; author reply 1324. PubMed ID: 20661171
[No Abstract] [Full Text] [Related]
20. The efficacy of intravitreal bevacizumab for acute central serous chorioretinopathy.
Aydin E
J Ocul Pharmacol Ther; 2013 Feb; 29(1):10-3. PubMed ID: 22925113
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
